Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
Mauro FR, Visentin A, Giannarelli D, Molinari MC, Proietti G, Petrella M, Angotzi F, Pepe S, Trentin L, Baroncelli S, Giombini E, Meschi S, Maggi F, Focosi D. Mauro FR, et al. Among authors: meschi s. Br J Haematol. 2023 May;201(3):564-567. doi: 10.1111/bjh.18701. Epub 2023 Feb 22. Br J Haematol. 2023. PMID: 36810731 No abstract available.
Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics.
Colavita F, Lapa D, Carletti F, Lalle E, Messina F, Rueca M, Matusali G, Meschi S, Bordi L, Marsella P, Nicastri E, Marchioni L, Mariano A, Scorzolini L, Ascoli Bartoli T, Di Caro A, Ippolito G, Capobianchi MR, Castilletti C; INMI COVID-19 Laboratory Team and INMI COVID-19 Study Group. Colavita F, et al. Among authors: meschi s. Open Forum Infect Dis. 2020 Sep 2;7(10):ofaa403. doi: 10.1093/ofid/ofaa403. eCollection 2020 Oct. Open Forum Infect Dis. 2020. PMID: 33527081 Free PMC article.
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, Antinori A; HIV‐VAC Study Group. Matusali G, et al. Among authors: meschi s. J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598. J Med Virol. 2024. PMID: 38624044
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, Antinori A; Mpox Vaccine Lazio Study Group. Mazzotta V, et al. Among authors: meschi s. EClinicalMedicine. 2024 Jan 12;68:102420. doi: 10.1016/j.eclinm.2023.102420. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38292040 Free PMC article.
Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.
Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, Mazzotta V, Colavita F, Fusto M, Cimini E, Notari S, D'Aquila V, Lanini S, Lapa D, Gagliardini R, Mariotti D, Giannico G, Girardi E, Vaia F, Agrati C, Maggi F, Antinori A. Vergori A, et al. Among authors: meschi s. Vaccines (Basel). 2023 Nov 22;11(12):1739. doi: 10.3390/vaccines11121739. Vaccines (Basel). 2023. PMID: 38140145 Free PMC article.
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Picchianti-Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, Agrati C, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti F, Spinelli FR, Corpolongo A, Chimenti MS, Ferraioli M, Sebastiani GD, Benucci M, Li Gobbi F, Santoro AP, Capri A, Puro V, Nicastri E, Goletti D. Picchianti-Diamanti A, et al. Among authors: meschi s. Vaccines (Basel). 2023 Nov 2;11(11):1684. doi: 10.3390/vaccines11111684. Vaccines (Basel). 2023. PMID: 38006015 Free PMC article.
111 results